RANI Rani Therapeutics
- 1.525
- +0.065+4.45%
- 1.599
- +0.074+4.84%
Rani Therapeutics News
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nanavaty Maulik
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Farquharson Andrew
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director DEBUONO LAUREEN
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Rometty Lisa Ann
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BUTEL JEAN LUC
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer McKinley Kate
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Imran Talat
Rani Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(8.66%),Steven Boyd(8.66%)
Rani Therapeutics | 10-Q: Q3 2024 Earnings Report
Rani Therapeutics | 8-K: Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-South Cone Investments Limited Partnership(28.2%),South Lake One LLC(28.2%), etc.
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner South Cone Investments Limited Partnership
Rani Therapeutics | 8-K: Current report
Rani Therapeutics | 424B5: Prospectus
Rani Therapeutics | 8-K: Current report
Rani Therapeutics | 10-Q: Q2 2024 Earnings Report
Rani Therapeutics | 8-K: Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
Rani Therapeutics | 8-K: Current report
No Data